Pilot Study in Patients With Head and Neck Cancer Finds That Derma Sciences, Inc. (DSCI)' MEDIHONEY® Reduces Hospital Stays in the U.K.  
9/21/2012 9:44:36 AM

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported an independent pilot study conducted in the U.K. showed that MEDIHONEY® may reduce the length of hospital stays by encouraging more rapid healing. The study, entitled “Randomised controlled feasibility trial on the use of medical grade honey following microvascular free tissue transfer to reduce the incidence of wound infection,” was conducted by Dr. Val Robson, RGN, B.Sc (Hons) Dip HE, Clinical Nurse Specialist Leg Ulcer Care, and colleagues from University Hospital Aintree, Liverpool, U.K. The article was published in the British Journal of Oral and Maxillofacial Surgery in June 2012.